Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of DOLUTEGRAVIR once daily and ELVITEGRAVIR/COBICISTAT once daily over 10 days following drug intake cessation in healthy volunteers

Trial Profile

Pharmacokinetics of DOLUTEGRAVIR once daily and ELVITEGRAVIR/COBICISTAT once daily over 10 days following drug intake cessation in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobicistat (Primary) ; Dolutegravir (Primary) ; Elvitegravir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 12 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 17 Dec 2015 Results published in the Journal of Antimicrobial Chemotherapy
    • 19 Feb 2015 Accrual to date is 112%, according to UK Clinical Trials Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top